tiprankstipranks
Trending News
More News >
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Price & Analysis

Compare
352 Followers

SNOA Stock Chart & Stats

$3.78
-$0.06(-2.19%)
At close: 4:00 PM EST
$3.78
-$0.06(-2.19%)

Bulls Say, Bears Say

Bulls Say
Low Financial LeverageLow debt relative to equity reduces near-term solvency risk and preserves flexibility to fund commercialization or R&D during loss-making periods. This durable low-leverage profile makes the company less vulnerable to interest rate shocks and gives management time to execute growth strategies before needing urgent refinancing.
Proprietary HOCl Platform & DistributionA proprietary HOCl formulation combined with a diversified Microcyn product portfolio addresses multiple billion-dollar markets (derm, wound, eye care, etc.). Durable commercial benefits arise from clinical backing, Medline distribution expansions, and international channels, which collectively support scalable, diversified revenue streams over the medium term.
Stable Gross Margins & Revenue ResilienceConsistent gross margins near 37–38% indicate cost-efficient manufacturing and sustainable product economics. Combined with modest top-line growth, this provides a foundation to leverage fixed costs and improve operating leverage as distribution and sales execution mature, supporting a durable path to margin improvement if revenue scales.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow means the business is not self-funding and remains reliant on external financing. Over 2–6 months, this constrains investment in commercialization and R&D, raises dilution risk, and limits strategic optionality; absent a sustained cash-flow inflection, growth plans may be delayed or curtailed.
Continued Operating LossesDeep negative net margins reflect that current revenues do not cover operating costs, signaling an entrenched profitability gap. Without meaningful revenue scale or structural cost reductions, losses are likely to persist, undermining long-term return potential and making it harder to reach self-sustaining operations within a medium-term time horizon.
Severe ROE Erosion & Shrinking EquityVery poor ROE and declining shareholder equity indicate cumulative capital erosion from sustained losses. This weakens the balance sheet over time, increases the probability of equity raises, and reduces financial flexibility, making it harder to fund growth without diluting existing shareholders or accepting restrictive financing terms.

Sonoma Pharmaceuticals News

SNOA FAQ

What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $1.75 and its highest was $6.92 in the past 12 months.
    What is Sonoma Pharmaceuticals’s market cap?
    Sonoma Pharmaceuticals’s market cap is $4.51M.
      When is Sonoma Pharmaceuticals’s upcoming earnings report date?
      Sonoma Pharmaceuticals’s upcoming earnings report date is Jul 15, 2026 which is in 130 days.
        How were Sonoma Pharmaceuticals’s earnings last quarter?
        Sonoma Pharmaceuticals released its earnings results on Feb 10, 2026. The company reported -$0.352 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.062.
          Is Sonoma Pharmaceuticals overvalued?
          According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Sonoma Pharmaceuticals pay dividends?
            Sonoma Pharmaceuticals does not currently pay dividends.
            What is Sonoma Pharmaceuticals’s EPS estimate?
            Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Sonoma Pharmaceuticals have?
            Sonoma Pharmaceuticals has 1,730,613 shares outstanding.
              What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
              Sonoma Pharmaceuticals reported an EPS of -$0.352 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went up 1.423%.
                Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
                Currently, no hedge funds are holding shares in SNOA
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Sonoma Pharmaceuticals

                  Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

                  Sonoma Pharmaceuticals (SNOA) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  China Pharma Holdings
                  RedHill Biopharma
                  Sunshine Biopharma
                  Shuttle Pharmaceuticals Holdings, Inc.

                  Ownership Overview

                  29.35%1.87%4.17%63.52%
                  29.35%
                  Insiders
                  4.17% Other Institutional Investors
                  63.52% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks